Citi lowered the firm’s price target on ProQR Therapeutics to $1.80 from $2.10 and keeps a Neutral rating on the shares. The analyst updated biotechnology models post the Q2 reports.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PRQR:
- ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
- PRQR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- ProQR Therapeutics announces anticipated upcoming events
- ProQR Therapeutics reports Q2 EPS (EUR 0.10c) vs (EUR 0.19) last year
- ProQR Announces Second Quarter 2023 Operating and Financial Results